{"id":"W4402538375","doi":"10.1007/s10637-024-01461-z","title":"A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; MAPK/ERK pathway; Internal medicine; Pharmacology; Chemistry; Kinase; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001796153,0.001176598,0.001238619,0.0003997045,0.0002965567,0.0004866266,0.0005220352,0.0008611152,0.002185824],"category_scores_gemma":[0.0006449721,0.0005306683,0.0007714895,0.0003461853,0.0006129824,0.0005210526,0.0002475265,0.002351208,0.0004751758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006102255,"about_ca_system_score_gemma":0.001358644,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006598869,"about_ca_topic_score_gemma":0.00203149,"domain_scores_codex":[0.9996154,0.0002260838,0.00001960616,0.0000546288,0.00003404174,0.00005011146],"domain_scores_gemma":[0.9995849,0.00008292429,0.00009604298,0.00002447047,0.00003220334,0.0001795416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5722397,0.1605144,0.01370801,0.001301371,0.001476505,0.0004539182,0.0004036393,0.002772992,0.1041181,0.0005042263,0.006884449,0.1356227],"study_design_scores_gemma":[0.5375756,0.4437537,0.01045005,0.00003182534,0.0003338142,0.0002251766,0.00003956125,0.001425875,0.0038244,0.0001452407,0.002176182,0.00001857498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993026,0.001692237,0.0005754986,0.0004062607,0.00008591054,0.002545413,0.0005244731,0.00005161211,0.001092465],"genre_scores_gemma":[0.9895557,0.001984549,0.002407159,0.0007256902,0.0001610893,0.00243195,0.001144672,0.00001616178,0.001573059],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002185824,"threshold_uncertainty_score":0.009499073,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01090793660721727,"score_gpt":0.2797415372715782,"score_spread":0.2688336006643609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}